Eisenmenger Syndrome Treatment Market Will Generate Record Revenue by 2029
The global eisenmenger syndrome treatment market is anticipated to grow at a CAGR during the forecast period. The triad of systemic-to-pulmonary congenital cardiovascular communication, pulmonary arterial disease, and cyanosis is called Eisenmenger syndrome. The major factor that drives the market is consistent regulatory approval to the key players operating in the global market for the treatment of Eisenmenger syndrome by providing drugs, and therapy is expected to drive the market growth. for instance-
July 2021- The Janssen Pharmaceutical Companies of Johnson
& Johnson announced that the US Food and Drug Administration (FDA) has
approved UPTRAVI (selexipag) injection for intravenous (IV) use for the
treatment of pulmonary arterial hypertension in adult patients with WHO
functional class (FC) II–III, who are temporarily unable to take oral therapy.
UPTRAVI IV is a therapeutic option that will allow patients to avoid short-term
treatment interruptions and stay on UPTRAVI therapy, as uninterrupted treatment
is considered key for individuals with PAH.
April 2021- The US FDA has granted a second approval to
treprostinil (Tyvaso) inhalation solution, for the patines. Tyvaso DPI is the
only therapy approved by the FDA for PH-ILD, when the blood pressure in the
lungs is high due to a disease that causes lung scarring. Moreover, the
convenience and portability of Tyvaso DPI make it an important new option for
patients with WHO Group 1 PAH and with WHO Group 3 PH-ILD, with the potential
for improving the quality of life for this patient population.
To Request a Sample of our Report on Eisenmenger
Syndrome Treatment Market: https://www.omrglobal.com/request-sample/eisenmenger-syndrome-treatment-market
Market Coverage
•
The market number available for – 2022-2030
•
Base year- 2022
•
Forecast period- 2023-2030
•
Segment Covered- by drug type, by diagnosis, by
distribution channel
•
Regions Covered- North America, Europe,
Asia-Pacific, Rest of the World
•
Competitive Landscape includes- AstraZeneca,
Bayer AG, Johnson & Johnson Pte. Ltd Pharmaceuticals Corp., Pfizer Inc.,
GlaxoSmithKline,Hikma Pharmaceuticals PLC, and others.
Eisenmenger Syndrome Treatment Market– Segmentation
By Drug Type
•
Antiarrhythmic Agents
•
Blood Thinning Agents
•
Endothelin Receptor Antagonist
•
Others
By Diagnosis
•
Blood tests
•
Electrocardiogram (ECG)
•
Chest X-ray
•
Echocardiogram
•
Computerized tomography (CT) scan
•
Magnetic resonance imaging (MRI)
•
Cardiac catheterization
By Distribution Channel
•
Hospital Pharmacies
•
Online Pharmacies
•
Retail Pharmacies
A
full Report of Eisenmenger Syndrome Treatment Market is Available @ https://www.omrglobal.com/industry-reports/eisenmenger-syndrome-treatment-market
Eisenmenger Syndrome Treatment Market by Region
North America
· United
States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest
of Europe
Asia-Pacific
· India
· China
· Japan
· South
Korea
· Rest
of APAC
Rest of the World
•
Latin America
•
Middle East and Africa
Company
Profiles
•
Eli Lilly and Co.
•
Gilead Sciences, Inc.
•
GlaxoSmithKline
•
Hikma Pharmaceuticals PLC
•
Lupin Ltd.
•
Merck & Co., Inc.
•
Natco Pharma Ltd.
•
Sun Pharma
•
Viatris Inc
•
Zydus Pharmaceuticals (USA) Inc.
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid data
sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data,
Request for Report Customization @ https://www.omrglobal.com/report-customization/eisenmenger-syndrome-treatment-market
About Orion Market Research
Orion Market Research (OMR) is
a market research and consulting company known for its crisp and concise
reports. The company is equipped with an experienced team of analysts and
consultants. OMR offers quality syndicated research reports, customized research
reports, consulting and other research-based services. The company also offers
Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another
subsidiary Encanto
Technologies.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment